London, United Kingdom, 25 June 2015 — A new report by Uniting to Combat NTDs highlights dramatic health and economic benefits from investing in combating neglected tropical diseases, making it one of the best buys in development.
The report, entitled Country Leadership and Collaboration on Neglected Tropical Diseases and launched today in London, comes on the heels of increased attention to NTDs at the World Health Assembly and inclusion in the recent G7 Leaders’ Declaration. The report finds that countries are increasingly taking ownership of NTD programmes, have started providing new funding and are pursuing innovative approaches to combat these devastating diseases. Yet while these new methods have produced substantial progress, further scale-up is necessary to reach the World Health Organization’s (WHO) 2020 targets.
“It is encouraging to see increased state-level engagement and strong leadership towards ownership of national control programs,” said Dr. Dirk Engels, WHO Director of the Department of Control of Neglected Tropical Diseases. “Sustained political commitment, innovative domestic financing and greater coordination can bring about game-changing treatments and care to millions of people and improve the prospects of achieving WHO’s goal of universal health coverage against NTDs.”
Helen Hamilton speaking at the UKCNTD co-hosted afternoon
of debate and presentations by leading stakeholders from the
With the Sustainable Development Goals (SDGs) set to be agreed later this year, 2015 is a once-in-a-generation opportunity to embed efforts to tackle NTDs in a global framework. The UKCNTD is committed to working with the new UK government to champion the fight against these devastating diseases on the global stage.”
Country Leadership and Collaboration on Neglected Tropical Diseases is the third progress report since a diverse public-private coalition of partners endorsed the 2012 London Declaration on NTDs, committing to achieve the WHO’s 2020 targets for 10 NTDs: diseases of poverty that that affect one in six people worldwide.
NTD Programmes Provide an Enormous Return on InvestmentNTDs keep children out of school, parents out of work, and cause stunting and impaired brain development, locking societies into endless cycles of poverty. According to the report, if countries achieve WHO’s 2020 targets, healthier citizens would generate an estimated US$623 billion in increased productivity between 2015 and 2030 – meaning that for each $US1 invested in NTD scale-up, endemic countries would see productivity gains of US$51 from 2015-2020 and US$184 for 2021-2030.
The report also shows for the first time the full burden of illness, disability, and deaths caused by NTDs, finding it at the same order of magnitude as the “Big Three” diseases: HIV/AIDS, tuberculosis and malaria.
Affected Countries are Increasingly Leading the Fight against NTDsEndemic countries are increasing domestic funding for NTDs and innovating to find new ways to deliver critical drugs. In doing so, they are improving coverage rates and making strides toward eliminating these diseases, with many already achieving elimination goals for individual diseases.
- Global coverage is increasing: approximately 785 million people (43% of at-risk populations) were reached with at least one drug, compared to around 35% in 2008.
- 126 cases of Guinea worm disease were reported in 2014, a staggering 99.99% drop since 1986. Only 5 cases have been reported so far in 2015.
- Of the 81 countries endemic for Lymphatic filariasis (LF), 25 countries (31%) are no longer in need of mass drug administration (MDA), including 10 which have successfully eliminated transmission.
- Fewer than 4,000 new cases of human African trypanosomiasis (also known as sleeping sickness) were reported to WHO last year, the lowest level in at least 75 years.
Since December 2014, 27 Ministers of Health pledged to take ownership and increase local investment in NTD efforts as part of the Addis Ababa NTD Commitment. Several countries have already taken on primary responsibility for financing their NTD programs: Bangladesh and the Philippines pay for 85% and 94% of their NTD programs, respectively, and Honduras recently became the first Latin American country to launch a national NTD programme fully financed by the government.
"The global effort to control and eliminate neglected tropical diseases must be led by the countries themselves,” said Kesetebirhan Admasu, Minister of Health, Ethiopia. “Through the Addis Commitment, and with the support of the international community, we will do whatever is necessary to see an end to these terrible diseases."
Global Coalition, Including Private Sector, Champions New Way to Help World’s Poorest
The backbone of these efforts is a diverse and committed public-private partnership that champions a new way of improving the lives of the world’s poorest people. As part of this partnership, pharmaceutical companies have donated 3.5 billion NTD treatments since the launch of the London Declaration and are committed to donate about $17.8 billion worth of NTD drugs through 2020, making it the largest drug donation programme in the world. Since 2012, there has been a 36% increase in donated drugs.
“Debilitating illnesses like lymphatic filariasis are on the retreat, partly due to public-private partnerships that help make sure donated medicines and essential healthcare reach those who need them most,” said Andy Wright, vice-president for global health programmes at GSK and chair of the Partnership for Disease Control Initiatives. “These collective efforts provide a powerful blueprint for working together to free communities from the burden of disease and enabling them to thrive.”
Other partners are collaborating to find innovative ways to advance NTD progress. This includes the Global Trachoma Mapping Project, the largest infectious disease mapping exercise in history; the formation of a Global Schistosomiasis Alliance to improve coverage for the disease and galvanize progress; an NTD modelling consortium aimed at better understanding effective control strategies in particular settings; and innovative research into new drugs, diagnostic tools and operational approaches.
Despite progress, the report identifies several areas where progress must be accelerated:
- Coverage rates: While more people are being reached, improvement in many places remains too low to achieve set goals. A scorecard released with the report shows progress against schistosomiasis lags behind other diseases despite the availability of a simple treatment.
- New diagnostics and tools: Reaching WHO roadmap targets for a number of these diseases relies on new diagnostics and tools, some of which are still in development, underscoring the importance of prioritizing research and development.
- Funding: Scaling up programmes to address these gaps requires additional funding. The report cites an annual delivery funding gap of US$200-300 million between now and 2020. The WHO estimates that low- and middle-income countries could fully fund their share of universal coverage against NTDs with less than 0.1% of domestic spending on health.